LifeStance Health's third quarter results drew a strongly positive market reaction, reflecting management’s focus on clinician productivity and operational efficiency. CEO David Bourdon attributed the company’s performance to record organic visit growth, driven by both increased clinician hiring and improved productivity. Initiatives such as the Cash Incentive Program and new technology platforms helped boost patient acquisition and clinician engagement. Bourdon emphasized that the hybrid model of in-person and virtual care, as well as a focus on commercial insurance, provided stability amid broader industry changes.
Is now the time to buy LFST? Find out in our full research report (it’s free for active Edge members).
LifeStance Health Group (LFST) Q3 CY2025 Highlights:
- Revenue: $363.8 million vs analyst estimates of $355.6 million (16.3% year-on-year growth, 2.3% beat)
- Adjusted EPS: $0.01 vs analyst estimates of $0.04 ($0.03 miss)
- Adjusted EBITDA: $40.21 million vs analyst estimates of $35.15 million (11.1% margin, 14.4% beat)
- Revenue Guidance for Q4 CY2025 is $378 million at the midpoint, roughly in line with what analysts were expecting
- EBITDA guidance for the full year is $149 million at the midpoint, above analyst estimates of $143.6 million
- Operating Margin: 2%, up from 0% in the same quarter last year
- Sales Volumes rose 10.6% year on year (12.7% in the same quarter last year)
- Market Capitalization: $2.51 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From LifeStance Health Group’s Q3 Earnings Call
- Craig Hettenbach (Morgan Stanley) asked about the durability of productivity gains. CEO David Bourdon confirmed that initiatives such as the Cash Incentive Program and AI-driven tools are “durable” and will be supplemented by additional enhancements in coming quarters.
- Lisa Gill (JPMorgan) inquired about trends in revenue per visit and acquisition strategy. CFO Ryan McGroarty noted revenue per visit remained flat as expected, while Bourdon clarified that acquisitions will focus on geographic expansion and complement organic growth.
- Matthew Mardula (William Blair) questioned the impact of productivity initiatives on clinician retention. Bourdon explained retention remains stable and pointed to regional success as evidence that broader improvement is achievable.
- Brian Tanquilut (Jefferies) asked about the rationale for maintaining revenue guidance and the Calm partnership’s growth prospects. McGroarty emphasized that guidance reflects balanced growth expectations, while Bourdon highlighted Calm as a source of new, younger patient referrals.
- Kevin Caliendo (UBS Investment Bank) asked about the reason for margin step-down in Q4 guidance. McGroarty explained pulling forward investments to support 2026 growth, particularly in business development and local market outreach.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be tracking (1) the sustainability of clinician productivity improvements and retention rates, (2) the effectiveness of technology and AI investments in driving further operating leverage, and (3) the pace of new referral partnerships and specialty service adoption. These factors, along with any developments in payer dynamics or acquisition activity, will be critical for assessing LifeStance’s ability to scale efficiently and maintain profitability.
LifeStance Health Group currently trades at $6.37, up from $4.79 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).
High-Quality Stocks for All Market Conditions
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.